CoChat

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

Open access
Beconi, Maria, Aziz, Omar, Matthews, Kim, Moumné, Lara, O’Connell, Catherine, Yates, Dawn, Clifton, Steven, Pett, Hannah, Vann, Julie, Crowley, Lynsey, Haughan, Alan F., Smith, Donna L., Woodman, Ben, Bates, Gillian P., Brookfield, Fred, Bürli, Roland W., McAllister, George, Dominguez, Celia, Munoz-Sanjuan, Ignacio, Beaumont, Vahri · 2012 · PLoS ONE
Cited by 42

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Histone deacetylase (HDAC) inhibitors have received considerable attention as potential therapeutics for a variety of cancers and neurological disorders. Recent publications on a class of pimelic diphenylamide HDAC inhibitors have highlighted their promise in the treatment of the neurodegenerative diseases Friedreich's ataxia and Huntington's disease, based on efficacy in cell and mouse models. These studies' authors have proposed that the unique action of these compounds compared to hydroxamic acid-based HDAC inhibitors results from their unusual slow-on/slow-off kinetics of binding, preferentially to HDAC3, resulting in a distinctive pharmacological profile and reduced toxicity. Here, we evaluate the HDAC subtype selectivity, cellular activity, absorption, distribution, metabolism and excretion (ADME) properties, as well as the central pharmacodynamic profile of one such compound, HDACi 4b, previously described to show efficacy in vivo in the R6/2 mouse model of Huntington's disease. Based on our data reported here, we conclude that while the in vitro selectivity and binding mode are largely in agreement with previous reports, the physicochemical properties, metabolic and p-glycoprotein (Pgp) substrate liability of HDACi 4b render this compound suboptimal to investigate central Class I HDAC inhibition in vivo in mouse per oral administration. A drug administration regimen using HDACi 4b dissolved in drinking water was used in the previous proof of concept study, casting doubt on the validation of CNS HDAC3 inhibition as a target for the treatment of Huntington's disease. We highlight physicochemical stability and metabolic issues with 4b that are likely intrinsic liabilities of the benzamide chemotype in general.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0044498

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 42

Metadata

Authors
Beconi, M., Aziz, O., Matthews, K., Moumné, L., O’Connell, C., Yates, D., Clifton, S., Pett, H., Vann, J., Crowley, L., Haughan, A. F., Smith, D. L., Woodman, B., Bates, G. P., Brookfield, F., Bürli, R. W., McAllister, G., Dominguez, C., Munoz-Sanjuan, I., & Beaumont, V.
Venue
PLoS ONE
Published
2012-09-04
Volume
7
Issue
9
Pages
e44498
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2000500943
Cited by
42
References
8
FWCI
2.56
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo. https://app.cochat.ai/papers/10.1371/journal.pone.0044498
The paper
Beconi, M., Aziz, O., Matthews, K., Moumné, L., O’Connell, C., Yates, D., Clifton, S., Pett, H., Vann, J., Crowley, L., Haughan, A. F., Smith, D. L., Woodman, B., Bates, G. P., Brookfield, F., Bürli, R. W., McAllister, G., Dominguez, C., Munoz-Sanjuan, I., & Beaumont, V. (2012). Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo. PLoS ONE. https://doi.org/10.1371/journal.pone.0044498

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.